Overall, 2019 was a good recovery year for the US Joint Fluid market with Single-injection treatment options at the helm
For Q419, revenue in the US Joint Fluid market was up, recovering fairly well from a year ago according to SmartTRAK Financial Dashboard. Aggregate growth for the quarter was attributable to a double-digit revenue growth in single injection. Stronger demand and heavy product push in that segment, especially at year-end, was offset to a certain extent by revenue declines in 3- and 5-injections.
Among the many topics covered in the comprehensive Q419 US Joint Fluid Market Recap* are: